U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H19N3O
Molecular Weight 281.3523
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENTOLAMINE

SMILES

CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(O)=CC=C3

InChI

InChIKey=MRBDMNSDAVCSSF-UHFFFAOYSA-N
InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)

HIDE SMILES / InChI
Molecular Formula C17H19N3O
Molecular Weight 281.3523
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00692 | https://www.drugs.com/pro/phentolamine.html | http://reference.medscape.com/drug/regitine-oraverse-phentolamine-342392 | https://www.ncbi.nlm.nih.gov/pubmed/26180030

Phentolamine (trade name Regitine) is a reversible nonselective α-adrenergic antagonist used for the control of hypertensive emergencies, most notably due to pheochromocytoma. Phentolamine produces its therapeutic actions by competitively blocking alpha-adrenergic receptors (primarily excitatory responses of smooth muscle and exocrine glands), leading to a muscle relaxation and a widening of the blood vessels. This widening of the blood vessels results in a lowering of blood pressure. The action of phentolamine on the alpha-adrenergic receptors is relatively transient and the blocking effect is incomplete. The drug is more effective in antagonizing responses to circulating epinephrine and/or norepinephrine than in antagonizing responses to mediator released at the adrenergic nerve ending. Phentolamine also stimulates β-adrenergic receptors and produces a positive inotropic and chronotropic effect on the heart and increases cardiac output. Phentolamine is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine is also indicated for the diagnosis of pheochromocytoma by the Phentolamine blocking test. Acute and prolonged hypotensive episodes, tachycardia, and cardiac arrhythmias have been reported. In addition, weakness, dizziness, flushing, orthostatic hypotension, nasal stuffiness, nausea, vomiting, and diarrhea may occur.

Originator

Tappi, G.|Forni, P.V.
3
Sources: Annali di Chimica Applicata (1948), 38, 602-13.

Approval Year

1952
115
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 3.7 nM [Kd]
Antagonist
2778
 16.6 nM [Kd]
Antagonist
2778
 5.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
REGITINE

Approved Use

Phentolamine Mesylate for Injection is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine Mesylate for Injection is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine Mesylate for Injection is also indicated for the diagnosis of pheochromocytoma by the phentolamine blocking test.

Launch Date

1952
Primary
Approved
8429
REGITINE

Approved Use

Phentolamine Mesylate for Injection is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine Mesylate for Injection is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine Mesylate for Injection is also indicated for the diagnosis of pheochromocytoma by the phentolamine blocking test.

Launch Date

1952
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
67.05 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/24452521
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENTOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
197.59 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/24452521
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENTOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.32 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/24452521
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENTOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Disc. AE: Rhinitis, Vomiting...
AEs leading to
discontinuation/dose reduction:
Rhinitis
Vomiting
Nausea
Diarrhea
Headache
Dizziness
Tachycardia
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Disc. AE: Dyspnea, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Dyspnea (0.84%)
Tachycardia (0.84%)
Epistaxis (0.84%)
Cephalgia (0.84%)
Flushing (serious, 0.84%)
Chest pain (serious, 0.84%)
Shortness of breath (serious, 0.84%)
Tachycardia (serious, 0.84%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
5 mg single, intravenous|intramuscular
Recommended
Dose: 5 mg
Route: intravenous|intramuscular
Route: single
Dose: 5 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
unhealthy
Health Status: unhealthy
Condition: Pheochromocytoma
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
Disc. AE: Myocardial infarction, Cerebrovascular spasm...
AEs leading to
discontinuation/dose reduction:
Myocardial infarction
Cerebrovascular spasm
Cerebral vascular occlusion
Hypotension
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
AEs

AEs

AESignificanceDosePopulation
Diarrhea Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Dizziness Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Headache Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Nausea Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Rhinitis Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Tachycardia Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Vomiting Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Cephalgia 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Dyspnea 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Epistaxis 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Tachycardia 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Chest pain serious, 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Flushing serious, 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Shortness of breath serious, 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Tachycardia serious, 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Cerebral vascular occlusion Disc. AE
5 mg single, intravenous|intramuscular
Recommended
Dose: 5 mg
Route: intravenous|intramuscular
Route: single
Dose: 5 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
unhealthy
Health Status: unhealthy
Condition: Pheochromocytoma
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
Cerebrovascular spasm Disc. AE
5 mg single, intravenous|intramuscular
Recommended
Dose: 5 mg
Route: intravenous|intramuscular
Route: single
Dose: 5 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
unhealthy
Health Status: unhealthy
Condition: Pheochromocytoma
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
Hypotension Disc. AE
5 mg single, intravenous|intramuscular
Recommended
Dose: 5 mg
Route: intravenous|intramuscular
Route: single
Dose: 5 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
unhealthy
Health Status: unhealthy
Condition: Pheochromocytoma
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
Myocardial infarction Disc. AE
5 mg single, intravenous|intramuscular
Recommended
Dose: 5 mg
Route: intravenous|intramuscular
Route: single
Dose: 5 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
unhealthy
Health Status: unhealthy
Condition: Pheochromocytoma
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:8081
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8081
ChemicalBook
CB6665216
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6665216
MolPort
MolPort-000-771-097
https://www.molport.com/shop/molecule-link/MolPort-000-771-097
MolPort
MolPort-001-783-569
https://www.molport.com/shop/molecule-link/MolPort-001-783-569
ZINC
ZINC000000020251
http://zinc15.docking.org/substances/ZINC000000020251
eMolecules
31790003
https://www.emolecules.com/cgi-bin/more?vid=31790003
eMolecules
975745
https://www.emolecules.com/cgi-bin/more?vid=975745
PubMed

PubMed

TitleDatePubMed
Effects of phentolamine, dihydroergocristine and isoxsuprine on the blood pressure and heart rate in normotensive, hypotensive and hypertensive rats.
1975
A study of the sympathomimetic action of guanethidine on the isolated anococcygeus muscle of the rat.
1978 Feb
Chronic treatment with antidepressant drugs: potentiation of apomorphine-induced aggressive behaviour in rats.
1979 Aug
Effects of pretreatment with 6-hydroxydopamine or noradrenergic receptor blockers on the clonidine-induced distruption of conditioned avoidance responding.
1979 Sep 1
Noradrenergic influences on sound-induced seizures.
1980 Aug
Electrophysiologic properties of hydralazine in man.
1980 Sep
Mediation of renin release in essential hypertension by alpha-adrenoreceptors.
1981 Nov-Dec
Pharmacological characterisation of the alpha-adrenoceptors responsible for a decrease of blood pressure in the nucleus tractus solitarii of the rat.
1981 Sep
Alpha-adrenoceptor blockade by phentolamine causes beta-adrenergic vasodilation by increased catecholamine release due to presynaptic alpha-blockade.
1982 Jan-Feb
Some functional changes in experimentally induced cardiac overload.
1983
Contribution of alpha-adrenoceptor activation to the pathogenesis of norepinephrine cardiomyopathy.
1983 Apr
Involvement of adenosine receptor activities in aggressive responses produced by clonidine in mice.
1984
A lethal complication of papaverine-induced priapism.
1991 Jan
Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning.
1992 Jul
Effects of adrenergic blockers on central nervous system-mediated hyperglycemia in fed rats.
1992 May
Presynaptic alpha 2-autoreceptors in brain cortex: alpha 2D in the rat and alpha 2A in the rabbit.
1993 Jul
Further characterization of human alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs.
1994 Jan 24
Reasons for high drop-out rate with self-injection therapy for impotence.
1994 Sep
Involvement of the sympathetic postganglionic neuron in capsaicin-induced secondary hyperalgesia in the rat.
1995 Mar
Contribution of peripheral alpha 1A-adrenoceptors to pain induced by formalin or by alpha-methyl-5-hydroxytryptamine plus noradrenaline.
1996 Apr 22
Cocaine-associated myocardial infarction.
1996 Aug
Neural mechanism of pressor action of nitric oxide synthase inhibitor in anesthetized monkeys.
1996 Sep
Cocaine-induced hypertension: role of the peripheral sympathetic system.
1999 Aug
Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study.
1999 Feb
Phentolamine reduces myocardial injury and mortality in a rat model of phenylpropanolamine poisoning.
2001
Role of the alpha(1)- and alpha(2)-adrenoceptors of the paraventricular nucleus on the water and salt intake, renal excretion, and arterial pressure induced by angiotensin II injection into the medial septal area.
2001 Apr
Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like antagonists.
2001 Jul 6
Effect of sustained adrenergic receptors stimulation and blockade on lactate threshold in rats.
2001 Sep
Physiological antagonism between ventricular beta 1-adrenoceptors and alpha 1-adrenoceptors but no evidence for beta 2- and beta 3-adrenoceptor function in murine heart.
2002 May
Effects of intravenous dobutamine on coronary vasomotion in humans.
2003 Nov 5
Chromatography studies on bio-affinity of nine ligands of alpha1-adrenoceptor to alpha1D subtypes overexpressed in cell membrane.
2004 Aug
[Lessons learned from anesthetic management of pheochromocytoma resection: a report of three cases].
2004 Dec
A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.
2009 Nov 1
Local and systemic toxicity of intraoral submucosal injections of phentolamine mesylate (OraVerse).
2009 Winter
Characterization of a β-adrenergic-like octopamine receptor from the rice stem borer (Chilo suppressalis).
2012 Aug 1
Insights into the mechanisms mediating hyperglycemic and stressogenic outcomes in rats treated with monocrotophos, an organophosphorus insecticide.
2012 Mar 29
Acute effects of a sarin-like organophosphorus agent, bis(isopropyl methyl)phosphonate, on cardiovascular parameters in anaesthetized, artificially ventilated rats.
2013 Oct 1
Patents

Patents

CH262433
3

Sample Use Guides

In Vivo Use Guide
Prevention or control of hypertensive episodes in the patient with pheochromo-cytoma. For preoperative reduction of elevated blood pressure, 5 mg of Phentolamine mesylate (1 mg for children) is injected intravenously or intramuscularly 1 or 2 hours before surgery, and repeated if necessary. During surgery, Phentolamine mesylate (5 mg for adults, 1 mg for children) is administered intravenously as indicated, to help prevent or control paroxysms of hypertension, tachycardia, respiratory depression, convulsions, or other effects of epinephrine intoxication.
Route of Administration: Other
In Vitro Use Guide
Cancer cell lines, PC-3, DU-145, NCI/ADR-RES, and SKOV3 were used for activity evaluation. Cells were seeded in 96-well plates. After 24 hr, cells were fixed with 10% trichloroacetic acid (TCA) representing cell population at time zero (T0). After additional incubation of 0.1% DMSO or phentolamine for 48 hr, cells were fixed with 10% TCA and SRB at 0.4% (w/v) in 1% acetic acid was added to stain cells. Unbound SRB was washed out. SRB bound cells were solubilized with 10mM Trizma base.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:20:45 GMT 2023
Edited
by admin
on Fri Dec 15 15:20:45 GMT 2023
Record UNII
Z468598HBV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHENTOLAMINE
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
PHENTOLAMINE [MI]
Common Name English
Phentolamine [WHO-DD]
Common Name English
3-((4,5-DIHYDRO-1H-IMIDAZOL-2-YLMETHYL)(4-METHYLPHENYL)AMINO)PHENOL
Systematic Name English
PHENTOLAMIN
Common Name English
phentolamine [INN]
Common Name English
PHENTOLAMINE [HSDB]
Common Name English
PHENTOLAMINE [VANDF]
Common Name English
Classification Tree Code System Code
WHO-VATC QV03AB36
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
NCI_THESAURUS C29713
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
NDF-RT N0000175553
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
WHO-ATC C04AB01
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
WHO-ATC V03AB36
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
NDF-RT N0000000099
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
WHO-VATC QC04AB01
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
Code System Code Type Description
SMS_ID
100000082263
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
NCI_THESAURUS
C62066
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
EPA CompTox
DTXSID4023462
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
RXCUI
8153
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY RxNorm
PUBCHEM
5775
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
CAS
50-60-2
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
MESH
D010646
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
IUPHAR
502
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
FDA UNII
Z468598HBV
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
DAILYMED
Z468598HBV
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
DRUG BANK
DB00692
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
HSDB
3382
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
MERCK INDEX
m8646
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
PHENTOLAMINE
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
CHEBI
8081
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
EVMPD
SUB09785MIG
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
INN
22
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
ChEMBL
CHEMBL597
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
DRUG CENTRAL
2142
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-053-1
Created by admin on Fri Dec 15 15:20:46 GMT 2023 , Edited by admin on Fri Dec 15 15:20:46 GMT 2023
PRIMARY
Related Record Type Details
Structure of PHENTOLAMINE MESYLATE
SALT/SOLVATE -> PARENT
ALPHA-2A ADRENERGIC RECEPTOR
TARGET -> AGONIST
SHORT-ACTING
Structure of PHENTOLAMINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
ALPHA-1A ADRENERGIC RECEPTOR
TARGET -> AGONIST
Related Record Type Details
Structure of PHENTOLAMINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966